VRDN Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. (VRDN) is expected to report earnings on February 3, 2027, before the market open. The consensus earnings estimate is a loss of $0.81 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +11.3% since its last earnings release on November 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Viridian Therapeutics, Inc.
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.